Table 5 EBCT score distribution and positive predicted values in studies of asymptomatic patients
| Â | Reported classification | Simplified classification | ||||
|---|---|---|---|---|---|---|
Study | EBCT category | Number (%) of patients | Number (%) with outcome | EBCT Category | Number (%) of patients | Number (%) with outcome |
1. Wong et al. [6] | 0 | 398 (42.9) | 4 (1.0) | Low | Â | Â |
|  | 1–15 | 133 (14.3) | 1 (0.8) | Low | 531 (57.2) | 5 (0.1) |
|  | 16–80 | 134 (14.4) | 5 (3.7) | Moderate |  |  |
|  | 81–270 | 131 (14.1) | 7 (5.3) | Moderate | 265 (28.6) | 12 (4.5) |
|  | ≥271 | 132 (14.2) | 11 (8.3) | High | 132 (14.2) | 11 (8.3) |
| Â | Total | 928 | 28 | Â | Â | Â |
2. Raggi et al. [7] | 0 | 292 (46.2) | 1 (0.3) | Low | 292 (46.2) | 1 (0.3) |
|  | 1–99 | 219 (34.7) | 12 (5.5) | Moderate |  |  |
|  | 100–400 | 74 (11.7) | 8 (10.8) | Moderate | 293 (46.3) | 20 (6.8) |
| Â | >400 | 47 (7.4) | 6 (12.8) | High | 47 (7.4) | 6 (7.4) |
| Â | Total | 632 | 27 | Â | Â | Â |
3. Kondos et al. [8] | 0 | 1816 (32.2) | 5 (0.3) | Low | 1816 (32.2) | 5 (0.3) |
| Â | >0 | 3819 (67.8) | 53 (1.4) | Moderate/high | 3819 (67.8) | 53 (1.4) |
| Â | Total | 5635 | 58 | Â | Â | Â |
4. Shaw et al. [9] | ≤10 | 5946 (57.3) | 62 (1.0) | Low | 5946 (57.3) | 62 (1.0) |
|  | 11–100 | 2044 (19.7) | 53 (3.0) | Moderate |  |  |
|  | 101–400 | 1432 (13.8) | 54 (3.8) | Moderate | 3476 (33.5) | 107 (2.9) |
|  | 401–1000 | 623 (6.0) | 39 (6.3) | High |  |  |
| Â | >1000 | 332 (3.2) | 41 (12.4) | High | 955 (9.2) | 80 (8.4) |
| Â | Total | 10377 | 249 | Â | Â | Â |
5. Greenland et al. [10] | 0 | 316 (30.7) | 14 (4.4) | Low | 316 (30.7) | 14 (4.4) |
|  | 1–100 | 321 (31.2) | 21 (6.5) | Moderate |  |  |
|  | 101–300 | 171 (16.6) | 15 (8.8) | Moderate | 492 (47.8) | 36 (7.3) |
|  | ≥301 | 221 (21.5) | 34 (15.4) | High | 221 (21.5) | 34 (15.4) |
| Â | Total | 1029 | 84 | Â | Â | Â |
6. Arad et al. [11] | 0 | 1504 (25) | 8 (0.5) | Low | 1504 (25.0) | 8 (0.5) |
|  | 1–99 | 1973 (25) | 20 (1) | Moderate |  |  |
|  | 100–399 | 686 (25) | 38 (5.5) | Moderate | 2659 (50.0) | 58 (2.2) |
|  | ≥400 | 450 (25) | 63 (14) | High | 450 (25.0) | 63 (14.0) |
| Â | Total | 4613 | 129 | Â | Â | Â |
7. Taylor et al. [12] | 0 | 1261 (77.6) | 7 (0.6) | Low | 1381 (85.0) | 7 (0.6) |
|  | 1–9 | 120 (7.4) | 0 (0.0) | Moderate |  |  |
|  | 10–44 | 120 (7.4) | 2 (1.7) | Moderate | 120 (7.4) | 2 (1.7) |
| Â | >44 | 124 (7.6) | 5 (4.0) | Moderate/high | 124 (7.6) | 5 (4.0) |
| Â | Total | 1625 | 14 | Â | Â | Â |
8. Vliegenthart et al. [13] | 0–100 | 905 (50.4) | 7 (0.8) | Low | 905 (50.4) | 7 (0.8) |
|  | 101–400 | 425 (23.7) | 13 (3.1) | Moderate | 425 (23.7) | 13 (3.1) |
|  | 401–1000 | 269 (15.0) | 13 (4.5) | High |  |  |
| Â | >1000 | 196 (10.9) | 17 (8.7) | High | 365 (25.9) | 30 (8.2) |
| Â | Total | 1795 | 50 | Â | Â | Â |
9. LaMonte et al. [14] | 0 | 5472 (50.9) | 15 (0.3) | Low | 5472 (50.9) | 15 (0.3) |
|  | 1–38 (Men), 1–16 (Women) | 1760 (16.4) | 19 (1.1) | Moderate |  |  |
|  | 39–249 (Men), 17–112 (Women) | 1758 (16.4) | 62 (3.5) | Moderate | 3518 (32.8) | 81 (2.3) |
|  | ≥250(Men), ≥113 (Women) | 1756 (16.3) | 191 (10.9) | High | 1756 (16.3) | 191 (10.9) |
| Â | Total | 10746 | 287 | Â | Â | Â |